The PhRMA Foundation Drug Delivery Postdoctoral Fellowship provides US$60,000 per year in stipend support for 12, 18 or 24 months at an eligible U.S. university. The second 2027 funding cycle’s letter-of-intent (LOI) deadline was 30 October 2026 at 12:00 p.m. Eastern Time and is now closed. Only candidates invited after LOI review can submit a full application in March 2027.
PhRMA Foundation Drug Delivery Postdoctoral Fellowship 2027
The Foundation funds postdoctoral researchers at accredited U.S. doctoral-granting universities whose research advances therapeutically relevant drug-delivery technologies, pharmaceutical formulation and biomedical engineering. U.S. and non-U.S. citizens may be eligible if they meet the host and programme conditions.
| Programme | Drug Delivery Postdoctoral Fellowship — second 2027 funding cycle |
|---|---|
| Funder | PhRMA Foundation |
| Status | LOI closed; shortlisted applicants may be invited to submit full applications |
| Funding | US$60,000 per year in stipend support |
| Duration | 12, 18 or 24 months |
| Host | Accredited U.S. doctoral-granting university |
| Earliest start, second cycle | 1 August 2027 |
| Latest start, second cycle | 1 December 2027 |
Eligible Research Areas in Drug Delivery
The Drug Delivery programme targets therapeutic delivery problems, including drug formulation and dosing, novel delivery technologies, pharmacokinetic/pharmacodynamic performance, complex biological modalities and pharmaceutical manufacturing or CMC technologies.
- Formulations and delivery modalities that support effective drug exposure and response;
- Biopharmaceutics, pharmaceutical biotechnology and biomedical engineering;
- CMC approaches addressing complex molecular and biological products;
- Modelling, simulation and data analytics linking product attributes to in vivo performance.
Eligibility for the Second 2027 Drug Delivery Cycle
- U.S. and non-U.S. citizens may apply, but must be based at an accredited U.S. doctoral-granting university.
- A PhD, PharmD, MD or other appropriate terminal research doctorate is required.
- Candidates had to hold a postdoctoral research position when submitting the LOI.
- The doctoral degree must have been conferred on or after 1 January 2024, assessed using the official transcript.
- Applicants must have at least two first-author publications.
- Current NIH K99/R00 and NIH F-award recipients are ineligible. Institutional training-grant recipients may be eligible if they agree to relinquish that slot if awarded the fellowship.
- Simultaneous stipend support from another funding mechanism is not permitted during the fellowship. University supplementation may be permitted.
- Only one applicant per laboratory per funding cycle is permitted for the Drug Delivery programme; the laboratory must choose a predoctoral or postdoctoral applicant.
Applicants remaining in the laboratory in which they completed graduate research receive lower preference because the fellowship prioritises development of new research skills. Applicants who were invited to the first 2027 cycle could not also enter the second-cycle LOI competition; the official guidelines contain additional resubmission restrictions.
Stipend, Duration and Award Conditions
| Annual stipend | US$60,000 |
|---|---|
| Possible award periods | 12, 18 or 24 months |
| Indicative total at 24 months | US$120,000 in stipend support |
| Payment | Made to the university on the awardee’s behalf |
| Restrictions | Cannot be used for tuition, fringe benefits or institutional indirect costs |
| Continuation | Satisfactory progress report after ten months required for support beyond year one |
Support depends on continuing in an eligible university postdoctoral position. Funding is stipend support, not an unrestricted grant for equipment or institutional overhead. The award is non-transferable and the Foundation requires financial and progress reporting.
2027 Funding-Cycle Timeline
| Stage | Official schedule | Status on 7 November 2026 |
|---|---|---|
| Second-cycle LOI | 30 October 2026, noon ET | Closed |
| Invitations to full application | February 2027 | Pending |
| Full application for selected candidates | March 2027; exact instructions sent to invitees | Invitation-only |
| Second-cycle award notification | July 2027 | Scheduled |
| Second-cycle eligible start dates | 1 August–1 December 2027 | Future |
How the Drug Delivery Application Works
The programme uses a two-stage process managed in ProposalCentral. These steps describe the 2027 application route; new LOIs cannot be submitted for the closed second-cycle deadline.
- Stage 1 — LOI: Eligible researchers prepared a PhRMA Foundation Drug Delivery LOI through ProposalCentral by 30 October 2026, with a scientific summary and impact questions following Foundation instructions.
- Stage 2 — invitation: The Foundation evaluates LOIs and plans to invite selected researchers in February 2027.
- Stage 3 — full proposal: Only invited candidates complete a full application during March 2027, using the exact deadline, templates, research-plan attachments, supervisor support and letters specified in their invitation.
- Stage 4 — decision: The Foundation expects award announcements in July 2027. Future public entry points must be confirmed through the official programme page.
For subsequent cycles, applicants should coordinate with their university research office, proposed supervisor and references well before opening a new ProposalCentral submission. Do not use the closed 2026 deadline for a future cycle.
Frequently Asked Questions
Is the PhRMA Foundation Drug Delivery Fellowship open now?
No. The second 2027 cycle’s public LOI deadline was 30 October 2026 at noon ET.
Can I apply during March 2027?
Only if the Foundation selects your earlier LOI and invites you to submit a full application.
How much does the fellowship provide?
US$60,000 per year in stipend support for 12, 18 or 24 months.
Are international candidates eligible?
Yes, subject to the requirement to hold an eligible postdoctoral position at an accredited U.S. doctoral-granting university.
What are the doctoral degree and publication criteria?
The second-cycle rules require a qualifying doctorate awarded on or after 1 January 2024 and at least two first-author publications.
Is the VA-HOR fellowship the same programme?
No. VA-HOR focuses on health outcomes and value assessment and uses a separate application process.
Official Sources and Verification
| Fellowship | Drug Delivery Postdoctoral Fellowship |
|---|---|
| Public LOI status | Closed |
| 2027 second-cycle LOI deadline | 30 October 2026 at 12:00 p.m. ET |
| Selected applicants’ full proposals | March 2027, invitation only |
| Stipend | US$60,000 annually |
| Last verified | 7 November 2026 |
Source: PhRMA Foundation’s official second-cycle 2027 Drug Delivery programme guidance. Historical dates should not be used for a future competition unless the Foundation announces a new cycle.
Related U.S. Postdoctoral Opportunity
Researchers comparing U.S.-based fellowship routes may also review the University of Colorado Postdoctoral Fellowship 2026.
